Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01531153 · ClinicalTrials.gov registry record · NA
Cognitive Enhancement as a Target for Cocaine Pharmacotherapy
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 93
- Enrollment target
NCT01531153 is a NA study that has completed, run by Yale University. The registered enrollment target is 93 participants.
The verdict
NCT01531153, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 93 participants
- Enrollment target
Study Summary
Specific Aim #1: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in reducing cocaine use as measured by cocaine urine results and self-report days of use. Specific Aim # 2: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in improving attention, assessed with the Rapid Visual Information Processing (RVIP) and the Simple Reaction Time (SRT) tests Specific Aim # 3: To determine if improvement in attention during the first four weeks of treatment will mediate galantamine's efficacy in reducing cocaine use.
Interventions
- DRUG Placebo
- DRUG Galantamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01531153
The ClinicalTrials.gov registry entry for NCT01531153 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01531153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01531153 about?
NCT01531153 is a clinical study titled "Cognitive Enhancement as a Target for Cocaine Pharmacotherapy". Specific Aim #1: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in reducing cocaine use as measured by cocaine urine results and self-report days of use. Specific Aim # 2: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in improving attention...
What is the current status of trial NCT01531153?
This trial is currently completed. It is a NA study. The enrollment target is 93 participants. The study started on 2011-09. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01531153?
The interventions under investigation include: Placebo (DRUG), Galantamine (DRUG).
Who is sponsoring clinical trial NCT01531153?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.